Global Molecular Cancer Therapeutics 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR042510240

Publication Date:

April 25, 2025

Pages:

106

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Molecular Cancer Therapeutics market size was valued at US$ 164 million in 2024 and is forecast to a readjusted size of USD 317 million by 2031 with a CAGR of 10.0% during review period.
Molecular cancer therapeutics focuses on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Molecular Cancer Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Molecular Cancer Therapeutics market size and forecasts, in consumption value ($ Million), 2020-2031
Global Molecular Cancer Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Molecular Cancer Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Molecular Cancer Therapeutics market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Molecular Cancer Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Molecular Cancer Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Phoenix Molecular Designs, Prelude Therapeutics, Tempus, Bracco, iOmx Therapeutics, OncoDNA, Sapience Therapeutics, Caris Life Sciences, Hera Biolabs, CV6 Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Molecular Cancer Therapeutics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Monoclonal Antibodies
Small Molecule Inhibitors
麻豆原创 segment by Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
麻豆原创 segment by players, this report covers
Phoenix Molecular Designs
Prelude Therapeutics
Tempus
Bracco
iOmx Therapeutics
OncoDNA
Sapience Therapeutics
Caris Life Sciences
Hera Biolabs
CV6 Therapeutics
Carrick Therapeutics
Foundation Medicine
Cybrexa Therapeutics
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Molecular Cancer Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Molecular Cancer Therapeutics, with revenue, gross margin, and global market share of Molecular Cancer Therapeutics from 2020 to 2025.
Chapter 3, the Molecular Cancer Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Molecular Cancer Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Molecular Cancer Therapeutics.
Chapter 13, to describe Molecular Cancer Therapeutics research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Molecular Cancer Therapeutics by Type
1.3.1 Overview: Global Molecular Cancer Therapeutics 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Molecular Cancer Therapeutics Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Monoclonal Antibodies
1.3.4 Small Molecule Inhibitors
1.4 Global Molecular Cancer Therapeutics 麻豆原创 by Application
1.4.1 Overview: Global Molecular Cancer Therapeutics 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Lung Cancer
1.4.3 Breast Cancer
1.4.4 Colorectal Cancer
1.4.5 Leukemia
1.4.6 Others
1.5 Global Molecular Cancer Therapeutics 麻豆原创 Size & Forecast
1.6 Global Molecular Cancer Therapeutics 麻豆原创 Size and Forecast by Region
1.6.1 Global Molecular Cancer Therapeutics 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Molecular Cancer Therapeutics 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Molecular Cancer Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Molecular Cancer Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Molecular Cancer Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Molecular Cancer Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Molecular Cancer Therapeutics 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Phoenix Molecular Designs
2.1.1 Phoenix Molecular Designs Details
2.1.2 Phoenix Molecular Designs Major Business
2.1.3 Phoenix Molecular Designs Molecular Cancer Therapeutics Product and Solutions
2.1.4 Phoenix Molecular Designs Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Phoenix Molecular Designs Recent Developments and Future Plans
2.2 Prelude Therapeutics
2.2.1 Prelude Therapeutics Details
2.2.2 Prelude Therapeutics Major Business
2.2.3 Prelude Therapeutics Molecular Cancer Therapeutics Product and Solutions
2.2.4 Prelude Therapeutics Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Prelude Therapeutics Recent Developments and Future Plans
2.3 Tempus
2.3.1 Tempus Details
2.3.2 Tempus Major Business
2.3.3 Tempus Molecular Cancer Therapeutics Product and Solutions
2.3.4 Tempus Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Tempus Recent Developments and Future Plans
2.4 Bracco
2.4.1 Bracco Details
2.4.2 Bracco Major Business
2.4.3 Bracco Molecular Cancer Therapeutics Product and Solutions
2.4.4 Bracco Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Bracco Recent Developments and Future Plans
2.5 iOmx Therapeutics
2.5.1 iOmx Therapeutics Details
2.5.2 iOmx Therapeutics Major Business
2.5.3 iOmx Therapeutics Molecular Cancer Therapeutics Product and Solutions
2.5.4 iOmx Therapeutics Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 iOmx Therapeutics Recent Developments and Future Plans
2.6 OncoDNA
2.6.1 OncoDNA Details
2.6.2 OncoDNA Major Business
2.6.3 OncoDNA Molecular Cancer Therapeutics Product and Solutions
2.6.4 OncoDNA Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 OncoDNA Recent Developments and Future Plans
2.7 Sapience Therapeutics
2.7.1 Sapience Therapeutics Details
2.7.2 Sapience Therapeutics Major Business
2.7.3 Sapience Therapeutics Molecular Cancer Therapeutics Product and Solutions
2.7.4 Sapience Therapeutics Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Sapience Therapeutics Recent Developments and Future Plans
2.8 Caris Life Sciences
2.8.1 Caris Life Sciences Details
2.8.2 Caris Life Sciences Major Business
2.8.3 Caris Life Sciences Molecular Cancer Therapeutics Product and Solutions
2.8.4 Caris Life Sciences Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Caris Life Sciences Recent Developments and Future Plans
2.9 Hera Biolabs
2.9.1 Hera Biolabs Details
2.9.2 Hera Biolabs Major Business
2.9.3 Hera Biolabs Molecular Cancer Therapeutics Product and Solutions
2.9.4 Hera Biolabs Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Hera Biolabs Recent Developments and Future Plans
2.10 CV6 Therapeutics
2.10.1 CV6 Therapeutics Details
2.10.2 CV6 Therapeutics Major Business
2.10.3 CV6 Therapeutics Molecular Cancer Therapeutics Product and Solutions
2.10.4 CV6 Therapeutics Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 CV6 Therapeutics Recent Developments and Future Plans
2.11 Carrick Therapeutics
2.11.1 Carrick Therapeutics Details
2.11.2 Carrick Therapeutics Major Business
2.11.3 Carrick Therapeutics Molecular Cancer Therapeutics Product and Solutions
2.11.4 Carrick Therapeutics Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Carrick Therapeutics Recent Developments and Future Plans
2.12 Foundation Medicine
2.12.1 Foundation Medicine Details
2.12.2 Foundation Medicine Major Business
2.12.3 Foundation Medicine Molecular Cancer Therapeutics Product and Solutions
2.12.4 Foundation Medicine Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Foundation Medicine Recent Developments and Future Plans
2.13 Cybrexa Therapeutics
2.13.1 Cybrexa Therapeutics Details
2.13.2 Cybrexa Therapeutics Major Business
2.13.3 Cybrexa Therapeutics Molecular Cancer Therapeutics Product and Solutions
2.13.4 Cybrexa Therapeutics Molecular Cancer Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Cybrexa Therapeutics Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Molecular Cancer Therapeutics Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Molecular Cancer Therapeutics by Company Revenue
3.2.2 Top 3 Molecular Cancer Therapeutics Players 麻豆原创 Share in 2024
3.2.3 Top 6 Molecular Cancer Therapeutics Players 麻豆原创 Share in 2024
3.3 Molecular Cancer Therapeutics 麻豆原创: Overall Company Footprint Analysis
3.3.1 Molecular Cancer Therapeutics 麻豆原创: Region Footprint
3.3.2 Molecular Cancer Therapeutics 麻豆原创: Company Product Type Footprint
3.3.3 Molecular Cancer Therapeutics 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Molecular Cancer Therapeutics Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Molecular Cancer Therapeutics 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Molecular Cancer Therapeutics Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Molecular Cancer Therapeutics 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Molecular Cancer Therapeutics Consumption Value by Type (2020-2031)
6.2 North America Molecular Cancer Therapeutics 麻豆原创 Size by Application (2020-2031)
6.3 North America Molecular Cancer Therapeutics 麻豆原创 Size by Country
6.3.1 North America Molecular Cancer Therapeutics Consumption Value by Country (2020-2031)
6.3.2 United States Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Molecular Cancer Therapeutics Consumption Value by Type (2020-2031)
7.2 Europe Molecular Cancer Therapeutics Consumption Value by Application (2020-2031)
7.3 Europe Molecular Cancer Therapeutics 麻豆原创 Size by Country
7.3.1 Europe Molecular Cancer Therapeutics Consumption Value by Country (2020-2031)
7.3.2 Germany Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Molecular Cancer Therapeutics Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Molecular Cancer Therapeutics Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Molecular Cancer Therapeutics 麻豆原创 Size by Region
8.3.1 Asia-Pacific Molecular Cancer Therapeutics Consumption Value by Region (2020-2031)
8.3.2 China Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Molecular Cancer Therapeutics Consumption Value by Type (2020-2031)
9.2 South America Molecular Cancer Therapeutics Consumption Value by Application (2020-2031)
9.3 South America Molecular Cancer Therapeutics 麻豆原创 Size by Country
9.3.1 South America Molecular Cancer Therapeutics Consumption Value by Country (2020-2031)
9.3.2 Brazil Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Molecular Cancer Therapeutics Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Molecular Cancer Therapeutics Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Molecular Cancer Therapeutics 麻豆原创 Size by Country
10.3.1 Middle East & Africa Molecular Cancer Therapeutics Consumption Value by Country (2020-2031)
10.3.2 Turkey Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Molecular Cancer Therapeutics 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Molecular Cancer Therapeutics 麻豆原创 Drivers
11.2 Molecular Cancer Therapeutics 麻豆原创 Restraints
11.3 Molecular Cancer Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Molecular Cancer Therapeutics Industry Chain
12.2 Molecular Cancer Therapeutics Upstream Analysis
12.3 Molecular Cancer Therapeutics Midstream Analysis
12.4 Molecular Cancer Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Phoenix Molecular Designs
Prelude Therapeutics
Tempus
Bracco
iOmx Therapeutics
OncoDNA
Sapience Therapeutics
Caris Life Sciences
Hera Biolabs
CV6 Therapeutics
Carrick Therapeutics
Foundation Medicine
Cybrexa Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.